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Methods: Cartilage samples were obtained from multi-organ donors
at the University Hospital of Coimbra with approval by the Ethics
Committee. After enzimatic digestion, isolated chondrocytes were
cultured under non proliferating conditions to avoid dedifferentiation.
Essential oils prepared by distillation of the aerial parts of Lavandula
luisieri, Otanthus maritimus, Laserpitium elasii, Annona muricata and
Eryngium duriae subsp. juresianum were added to the chondrocyte
cultures, in at least 3 different concentrations, ranging from 0.0005
to 0.005% (v/v), 30 min before addition of IL-1, 10ng/mL and further
incubated for 18 h. The MTT reduction assay was used to rule out
cytotoxic effects. NO levels were measured by a colorimetric method
based on the Griess reaction. iNOS levels were evaluated by western
blot.
Results: Of the essential oils tested, 2 showed a signiﬁcant ability
to decrease IL-1-induced NO production and iNOS protein levels. L.
luisieri promoted the greatest inhibition (49.9±5.7%) in a concentration
of 0.005% (v/v). A concentration 5x lower, 0.0025%, still promoted a
signiﬁcant decrease (30.0±3.1%) of NO levels. Similarly, the essential
oil from E. duriae subsp. juresianum in concentrations of 0.0025% and
0.001% (v/v) decreased NO production by 38.8±12.8% and 24.6±3.7%,
respectively %. Both oils signiﬁcantly reduced iNOS levels. The effects
observed were achieved with concentrations that did not induce
cytotoxicity.
Conclusions: Among the essential oils screened, those from L. luisieri
and E. duriae subsp. juresianum are promising samples for further
fractionation in order to purify and identify the active component(s).
Future studies will be designed to fully characterize the mechanism of
action of such compound(s) and determine their potential usefulness as
anti-osteoarthritic agents.
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FOR THE PAIN IN KNEE AND HIP OSTEOARTHRITIS: SYSTEMATIC
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Background: Pain is a major problem concerning patients with
Osteoarthritis (OA). Duloxetine has shown to be effective as a central
acting analgesic in chronic back pain, ﬁbromyalgia and other rheumatic
conditions
Purpose: The aim of this study was to develop evidence-based
recommendations for the use of Duloxetine in the pain of patients with
OA of hip or knee.
Methods: A scientiﬁc committee from the Mexican College of
Rheumatology (CMR) selected clinically relevant questions concerning
the use of Duloxetine in OA. A systematic review of the literature for
randomized controlled trials (RCT) with Duloxetine as treatment for the
pain management in patients with OA was performed blinded by two
experts in systematic review.
Research strategy: We searched RCT using Duloxetine OA in
Medline/PubMed, EMBASE, ARTEMISA, LILACS and the Cochrane Library
in English or Spanish languages.
Selection Criteria: We included RCT, in which adults with knee and or
hip OA were treated with Duloxetine, considering as efﬁcacy outcome
variables: pain and or functional capacity, and safety: adverse events.
Quality of the articles was evaluated by ten experts with the Jadad
Score and CONSORT guidelines 2010. The level of evidence was appraised
according to the Oxford Levels of Evidence. An expert consensus meeting
took place in April 2011 including 12 rheumatologists when the scores
of Jadad and Consort evaluations were revised. Recommendations were
made during interactive workshops where the evidence was reviewed.
Agreement among participants and the impact of the recommendations
were systematically assessed using voting procedure in a plenary
session.
Results: A total of 12 references were identiﬁed, among which nine
were excluded because the intervention evaluated other conditions and
or consider animal models; two articles were included for efﬁcacy and
one for safety. There was a good quality of evidence in the three
articles assessed, in two rounds of discussion between experts. The
recommendations were formulated, including usefulness, population,
optimal dosage and safety. For efﬁcacy Duloxetine was evaluated by
experts as useful considering those patients with persistence intensive
pain (visual analogue scale >4), and with previous use of other analgesics,
without correlation with the disease stage (clinical and radiologic) The
secondary adverse events where reported correctly in the RCT and a safe
proﬁle was identiﬁed by consensus, looking more events with high dose,
but resolved with a scaling dosage administration: starting at 30mg the
ﬁrst week, and then increase at 60mg
Conclusions: Duloxetine is an effective and safety option for the
management of pain in OA of hip and knee in patients with history
of analgesics or NSAIDS and persistency of pain (more than 4 in VAS),
independently of the radiologic stage, at a starting dose of 30mg for
one week an after 60mgd, ingested with food. These recommendations
are evidence based and supported by a panel of the Mexican College of
Rheumatology specialists and experts. Further research has to be place
to evaluate the real cost-effectiveness of Duloxetine in the management
of pain in OA patients.
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A COMPARISON OF ANTI-INFLAMMATORY PROPERTIES OF WHOLE
BLOOD, PLATELET-RICH PLASMA, AND AN AUTOLOGOUS PROTEIN
SOLUTION IN IL-1b- AND TNFa-STIMULATED CHONDROCYTES
A.M. Matuska, K.M. O’Shaughnessey, J.E. Woodell-May. Biomet, Inc.,
Warsaw, IN, USA
Purpose: Autologous intra-articular injections of platelet-rich plasma
(PRP) have been investigated as a potential treatment for cartilage
degeneration. Degradation of the cartilage matrix, seen in early stage
osteoarthritis (OA), is believed to be driven by inﬂammatory cytokines
such as IL-1 and TNFa. These cytokines induce cells in the joint to produce
matrix metalloproteinases (MMPs) that in turn are responsible for
degradation of the cartilage matrix. An autologous protein solution (APS),
which is derived from PRP and contains anti-inﬂammatory cytokines,
has been developed. The purpose of this study was to determine if APS
can inhibit the production of MMP-13 from IL-1b- and TNFa-stimulated
chondrocytes more effectively than PRP.
Methods: Preparation of samples: Nine ml of PRP was prepared from 90ml
fresh whole blood (8.3% v/v ACD-A) using two disposable separation
devices containing a tuned density buoy (Biomet Biologics). Six ml of the
combined PRP output was transferred to a disposable device containing
polyacrylamide beads. The device was centrifuged and the APS was
collected. Cells in the whole blood (WB), remaining PRP, and APS were
lysed by processing 500ml of each sample at 5°C with protease inhibitor
and cell disruption glass beads in a cell disrupter (Scientiﬁc Industries).
The samples were centrifuged at 5°C for 20 minutes at 13,000 rpm
(11,500 g), and the lysate was removed and stored (−50°C) until use in
the assay.
Cell Assay: Human knee articular chondrocytes (NHAC, P5, Lonza Inc.)
were seeded in 12-well plates at 20,000 cells/cm2 in 2ml growth media
(Lonza). Two hours prior to the assay, media was exchanged with serum-
free. The treatment wells were pre-incubated with 25ml WB, PRP, or
APS in a transwell insert (Corning Inc.) for 2 hours before addition of
recombinant IL-1b (5 ng/ml) (Sigma) and TNFa (100ng/ml) (Prospec).
Negative control was untreated media, and positive control contained
only IL-1b (5 ng/ml) and TNFa (100ng/ml). Following incubation at 37°C
and 5% CO2 for 24 hours, the supernatant was removed and frozen
at −50°C. Cells were trypsinized and counted. The supernatant was
assayed for MMP-13 by ELISA (R&D Systems), and MMP-13 production
was normalized to cell number.
Statistical Analysis: A single-factor ANOVA with a post-hoc Fisher LSD
test (a = 0.05) was performed to determine statistically signiﬁcant
differences.
Results: APS was more capable of inhibiting MMP-13 production by
IL-1b- and TNFa-stimulated chondrocytes than an equal dose of WB
(p < 0.0001) or PRP (p =0.0003). WB had no effect on MMP-13 production
compared to the positive control (p = 0.4). PRP and APS inhibited
approximately 45% and 70% of MMP-13 production, respectively.
